Fate Therapeutics announced that the FDA has chosen its FT819 therapy for the Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program. This program supports faster manufacturing readiness for therapies with expedited clinical timelines, helping to accelerate FT819's development for treating moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis. FT819 is an off-the-shelf CAR T-cell therapy designed for outpatient use, aiming to improve accessibility for patients. The therapy also holds Regenerative Medicine Advanced Therapy (RMAT) designation, which alongside CDRP participation, may speed regulatory approval and commercial readiness as the company advances to Phase 2 clinical trials.
Verra Mobility shares dropped 41.2% in after-hours trading following Avis Budget Group's termination of their contract effective September 2026. This contract loss could reduce Verra's annual Commercial Services revenue by $135-$145 million and segme...
Netcapital Inc. shares surged 19.63% in after-hours trading following the announcement of a business update conference call scheduled for Thursday. The new CEO, Todd Violette, will discuss the company's transformation, priorities, and plans to grow i...
ISS has secured a seven-year contract with West Sussex County Council to deliver around 25,000 nutritious school meals daily to primary schools starting Q3 2026. The contract, valued at about DKK 100 million annually, emphasizes inclusivity and high ...
TGS ASA has secured a large 4D streamer contract offshore Angola, set to begin data acquisition in early July 2026 and last about eight months. This contract strengthens TGS's strategic presence in Africa and ensures vessel utilization into early 202...
Roche has introduced the Liver Disease Panel, the first comprehensive set of certified algorithms designed to improve the detection and management of chronic liver disease (CLD). This panel includes LiverPRO, an algorithm that uses routine blood mark...
